Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-30
2011-08-30
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S391700, C424S178100
Reexamination Certificate
active
08008442
ABSTRACT:
Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
REFERENCES:
patent: 5416064 (1995-05-01), Chari et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 6048970 (2000-04-01), Lal et al.
patent: 6329503 (2001-12-01), Afar et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6887975 (2005-05-01), Afar et al.
patent: 7053186 (2006-05-01), Afar et al.
patent: 7091186 (2006-08-01), Senter et al.
patent: 7166714 (2007-01-01), Afar et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2003/0060612 (2003-03-01), Goddard et al.
patent: 2003/0064397 (2003-04-01), Spancake et al.
patent: 2008/0226657 (2008-09-01), Doronina et al.
patent: 2008/0248053 (2008-10-01), Doronina et al.
patent: 0 834 563 (1998-04-01), None
patent: 0834563 (1998-04-01), None
patent: 1308459 (2003-05-01), None
patent: 1164691 (1999-06-01), None
patent: WO 94/09150 (1994-04-01), None
patent: WO 95/14772 (1995-06-01), None
patent: WO 98/18489 (1998-05-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 98/53071 (1998-11-01), None
patent: WO 99/06548 (1999-02-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/61469 (1999-02-01), None
patent: WO 99/62941 (1999-12-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 00/35937 (2000-06-01), None
patent: WO 00/77021 (2000-12-01), None
patent: WO 01/12662 (2001-02-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/40276 (2001-06-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO 01/57190 (2001-08-01), None
patent: WO 01/57276 (2001-08-01), None
patent: WO 01/57277 (2001-08-01), None
patent: WO 01/60860 (2001-08-01), None
patent: WO 01/72962 (2001-10-01), None
patent: WO 01/73032 (2001-10-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/86003 (2001-11-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 01/96388 (2001-12-01), None
patent: WO 02/10449 (2002-02-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO 02/26822 (2002-04-01), None
patent: WO 02/30268 (2002-04-01), None
patent: WO 02/057303 (2002-07-01), None
patent: WO 02/059260 (2002-08-01), None
patent: WO 02/095010 (2002-11-01), None
patent: WO 02/102993 (2002-12-01), None
patent: WO 02/102994 (2002-12-01), None
patent: WO 03/004622 (2003-01-01), None
patent: WO 03/009814 (2003-02-01), None
patent: WO 2005/081711 (2005-09-01), None
patent: WO 2005/113601 (2005-12-01), None
patent: WO 2006/034488 (2006-03-01), None
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”.
Rudikoff et al, Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
Colman P. M., Research in Immunology, 145:33-36, 1994.
Casset et al, Biochemical and Biophysical Research Communications, 2003, vol. 307, pp. 198-205.
Holm et al, Molecular Immunology, 2007, vol. 44, pp. 1075-1084.
Challita-Eid Pia M., et al., “Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo”, vol. 67, No. 12, pp. 5798-5805, (2007).
Faris M., et al., “Validation of STEAP-1 as a cell surface cancer therapeutic target”, Proceedings of the annual meeting of the American Association for Cancer Research, vol. 43, p. 947, (2002).
Abu-Threideh et al., Jun. 1998, EMBL/GENBAK/DDBJ Databases.
Abu-Threideh et al., Genbank (Accession No. 095034) National Library of Medicine, Bethesda MD, May 1, 1999.
Alberts et al., Molecular Biology of the Cell, 3rdedition (1994) p. 465.
Bellone et al., Immunolgoy Today (1999) 20(10):457-462.
Bowie et al, Science 247:1306-1310 (1990).
Burgess et al., J. Cell Biol. 111:2129-2138 (1990).
Cate et al., Genbank (Accession No. W86309) National Library of Medicine, Bethesda MD, Nov. 1998.
Database EMBL Nucleotide and Protein Sequences, Aug. 25, 1996, XP002128081, AA032221, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, May 13, 1997, XP002128082, AC002064, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, Jun. 15, 1998, XP002128084, AC004969 (clone DJ112E10), Hinxton, GB.
Database EMBL, “Human BAC Clone CTB-167B5 form 7q21, complete sequence,”, Jun. 17, 1998, XP002173859, AC003991, R. Waterston et al.
Database EMBL Nucleotide and Protein Sequences, May 1, 1999, XP002128083, O95034 (clone RG041D11), Hinxton, GB.
Diss et al., “Expression of skeletal muscle-type voltage-gated Na+ channel in rat and human prostate cancer cell lines,” FEBS Letters 427:5-10 (1998).
Dulcert et al., Genbank (Accession No. Y11840), National Library of Medicine, Bethesda MD, Feb. 11, 1999.
Fu et al., EMBO Journal 15:4392-4401 (1996).
Goldenberg, Clinical Therapeutics 20(2):309-318 (1999).
Greenspan et al, Nature Biotechnology 7:936-937 (1999).
Grimes et al., “Electrophysiological characterization of voltage-gated NA+ current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer,” Journal of Cellular Physiology 175:50-58 (1998).
Gutierrrez et al., “Activation of a Ca2+-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line,” Journal of Physiology 517:95-107 (1999).
Gura, Science 278:1041-1042 (1997).
Haverstick et al., “Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+entry,” Cancer Research pp. 1002-1008 (2000).
Herbert et al., The Dictionary of Immunology, Academic Press, 4thedition (1995).
Hubert et al., PNAS USA 96(25):14523-14528 (1999).
Lazar et al., Mol Cell. Biol. 8(3):1247-1252 (1988).
Lepple-Weinhues et al., “K+ channels and the intracellular calcium signal in human melanoma cell proliferation,” J. Membrane Biol. 151:149-157 (1996).
Marino et al., “Association between cell membrane potential and breast cancer,” Tumor Biol. 15:82-89 (1994).
McClean et al., Eur. J. of Cancer 29A:2243-2248 (1993).
Nie et al., “Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca2+-permeable channel,” Celll Calcium 22(2):75-82 (1997).
Pancrazio et al., “Voltage-dependent ion channels in small-cell lung cancer cells,” Cancer Research 49:5901-5906 (1989).
Reiger et al., Glossary of Genetics and Cytogenetics, Springer-Verlag (1976), p. 17.
Shantz et al., Int. J. Biochem. Cell Bio. 31:107-122 (1999).
Skryma et al., “Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation,” The Prostate 33:112-122 (1997).
Spitler, Cancer Biotherapy 10:1-3 (1995).
Hillier, et al., “The WashU-Merck EST Project,” EMBL Sequence Database, XP002128081, Aug. 25, 1996.
“WUGC:H—RG041D11.1 Protein (WUGSC: H—DJ1121E10.1 Protein) (Fragment),” EMBL Sequence Database, XP002128083, May 1, 1999.
“Homo sapiensPAC Clone DJ1121E10 from 7q21.1-q2, Complete Sequence,” EMBL Sequence Database, XP002128084, Jun. 15, 1998.
“Human BAC Clone RG016J04 from 7q21, Complete Sequence,” EMBL Sequence Database, XP002128082, May 13, 1997.
Boder, E.T. et al., “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity,” Proc. Natl. Acad. Sci. USA 97:10701-10705 (2000).
Chen, G. et al., “In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding
Challita-Eid Pia M.
Etessami Soudabeh
Faris Mary
Gudas Jean
Jakobovits Aya
Agensys, Inc.
Dreger Ginger R.
Halvorson Mark
Kresnak Mark T.
Popp, LLM Shan M.
LandOfFree
Antibodies and molecules derived therefrom that bind to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies and molecules derived therefrom that bind to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies and molecules derived therefrom that bind to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747272